Le Lzard
Classified in: Health
Subject: LAW

Carella, Byrne, Cecchi, Brody & Agnello, P.C.* Announces the Settlement of a Class-Action Lawsuit Involving Persons and Entities that Purchased, Paid For, and/or Provided Reimbursement for Effexor XR and/or its Generic Equivalent


*In association with Wexler Boley & Elgersma LLP, Spector Roseman & Kodroff, P.C., Miller Law LLC, Motley Rice LLC, Quantum Legal LLC, and The Dugan Law Firm, PLC

CHICAGO, June 14, 2024 /PRNewswire/ --

Legal Notice
Did You Purchase, Pay for, or Provide Reimbursement for Effexor XR and/or Its Generic Equivalent?
You Could Get Money from a Settlement

There is a Settlement in a class-action lawsuit with Wyeth (also known as Wyeth LLC and formerly known as Wyeth, Inc. and American Home Products); Wyeth Pharmaceuticals, Inc.;Wyeth-Whitehall Pharmaceuticals; and Wyeth Pharmaceuticals Company (collectively, "Wyeth") and Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively, "Teva"). The lawsuit claims that Wyeth and Teva unlawfully kept generic versions of Effexor XRoff the market, causing consumers and third-party payors to pay more for brand and generic Effexor XRthan they should have. Wyeth and Teva deny they did anything wrong. There has been a settlement with Wyeth; the lawsuit against Teva is ongoing. No one is claiming that Effexor XRis unsafe.

Who is included in the Settlement?

You may be included in the Settlement if you are a person or entity that purchased, paid for, and/or reimbursed some or all of the cost of Effexor XRor AB-rated generic versions of Effexor XRfor yourself, your family, or your members, employees, insureds, participants, or beneficiaries, from June 14, 2008 through May 31, 2011, in the following states: Arizona, California, Florida, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nevada, New Hampshire, New Mexico, New York, North Carolina, Oregon, Rhode Island, South Dakota, Tennessee, West Virginia, and Wisconsin.

A more detailed notice, including the full class definition and who is not included, is available at www.EffexorXRIndirectSettlement.com.

What does the Settlement provide?

Wyeth will pay $25.5 million into a Settlement Fund that will pay (1) money to eligible Class Members; (2) notice and administration costs; (3) service awards to the class representatives who brought the lawsuit; and (4) attorneys' fees, costs, and expenses.

How can I get a payment?

You must submit a valid claim form to apply for payment from the Settlement Fund. The amount of your payment will depend on the amount of Effexor XRor AB-rated generic versions of Effexor XRyou purchased and the number of claims that are filed. The Claim Forms, and information on how to submit them, are available at www.EffexorXRIndirectSettlement.com. Claim forms must be postmarked (if mailed) or received (if submitted online) on or before September 16, 2024.

What are my rights?

Even if you do nothing, you will be bound by the Court's decisions. If you want to keep your right to sue Wyeth yourself, you must exclude yourself by July 29, 2024. If you do not exclude yourself, you may object to the Settlement by July 29, 2024. Detailed instructions about how to act on these rights are available at www.EffexorXRIndirectSettlement.com.

The Court will hold a hearing on September 12, 2024 to consider whether to approve the Settlement, a request for attorneys' fees of up to 34% of the Settlement Fund, plus costs and expenses, and service awards to the class representatives. You or your own lawyer may appear and speak at the hearing at your own expense. The Court may change these deadlines or the hearing date and time. Check the website below for updates. Please do not call the Court or the Clerk of the Court for information about the Settlement.

For more information: 1-877-933-2882 www.EffexorXRIndirectSettlement.com

SOURCE Carella, Byrne, Cecchi, Brody & Agnello, P.C.; Wexler Boley & Elgersma LLP


These press releases may also interest you

at 05:17
Second Quarter 2024 Total revenue increased 12 per cent, 11 per cent at constant exchange rates, (CER), to SEK 5,442 M (4,872)Haematology revenue increased 13 per cent at CER to SEK 3,866 M (3,430), reflecting growth in all medicines, mainly driven...

at 05:05
CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion's Growth Opportunities Fund ("Forbion Growth"), Omega Funds...

at 05:00
Owing to different key contributing factors, the electroencephalography device market is expected to advance through the forecasted era at a promising CAGR...

at 04:23
Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has approved the...

at 04:05
Azafaros B.V. today announced positive topline data from its RAINBOW study, a Phase 2 clinical trial investigating nizubaglustat in patients with a genetic diagnosis of either GM2 gangliosidosis or Niemann-Pick disease type C (NPC). About the Trial...

at 03:30
EQT Life Sciences is pleased to share that the LSP Dementia Fund...



News published on and distributed by: